These findings extend our prior research on elevated CD38 levels in mature T-cell neoplasms and align with recent studies demonstrating CD38 expression in tumor cells of aggressive, treatment-resistant CTCL patients [3, 15]. This evidence concerns the gene CD38 and neoplasm.